Abstract
Desvenlafaxine succinate (DVS) inhibits serotonin reuptake selectively and is approved for major depressive disorders. This research investigated influence of DVS on modulating brain monoamine and oxidative stress in mice. The antiepileptic potential of DVS (10, 20, or 30 mg/kg/i.p.) in pentylenetetrazole (PTZ; 85 mg/kg) with i.p. route of administration, strychnine (STR; 75 mg/kg) with i.p. route, pilocarpine (400 mg/kg) with s.c. route and maximal electroshock MES-induced convulsion in mouse models. The activities of oxidative stress, i.e. superoxide dismutase (SOD), glutathione (GSH) and lipid peroxidation (LPO) as well as gamma-aminobutyric acid (GABA) in the brains of PTZ-induced convulsive mice. Treatment with DVS increased the latency to develop siezures and declined mortalities in rodents against PTZ, STR and pilocarpine-induced convulsions. Results of MES-leaded siezures revealed that DVS reduced tonic hind limb extension duration and mortalities significantly. Brain, SOD, GSH and GABA level were significantly (P<0.01) increased and LPO reduced significantly (P<0.01) after DVS treatment. Furthermore, the DVS did not show any motor coordination signs in the rotarod test. We demonstrated that the role of DVS in convulsion genesis in mice under control condition and attenuate the PTZ-induced oxidative damage.
Highlights
Desvenlafaxine succinate (DVS) is approved for management depression, chemically unrelated to other existing options (tricyclics/tetracyclic, dual-acting reuptake inhibitor of serotonin-norepinephrine (SNRI) (Solem et al, 2016)
Findings of our experiments revealed that STRinduced convulsions are moderately suppressed by DVS administration
Pretreatment with DVS showed significantly increased latencies for convulsion and duration of myoclonic jerks which may be due to increasing gamma-aminobutyric acid (GABA) levels. These findings suggest that DVS may have an effect on the GABA receptor, which shows the anti-convulsion potential
Summary
DVS is approved for management depression, chemically unrelated to other existing options (tricyclics/tetracyclic, dual-acting reuptake inhibitor of serotonin-norepinephrine (SNRI) (Solem et al, 2016). DVS is an atypical antidepressant which is used in neurological illnesses, blocks transporter proteins especially for neurotransmitters affecting mood, increase neurochemicals (5-HT and NE) at synaptic space. It is inhibits 5-HT reuptake ten times more affinity than norepinephrine (Deecher et al, 2006).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Brazilian journal of biology = Revista brasleira de biologia
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.